It is our mission to share the key learnings on how to objectively, fairly and ethically approach compassionate use requests and advance public health. CompAC is a model that has the potential for wider application within the industry.
We believe the CompAC model offers insights that can serve as an industry best practice for fair evaluation of compassionate use requests—and we are proud to be leading this discussion.
- These slides from a recent Patient Advocacy Summit contain information on how the pre-approval access landscape is changing now more than ever.
- This co-authored article by Drs. Amrit Ray and Art Caplan from the Journal of the American Medical Association details some of the ethical challenges that compassionate use faces.
- This web page hosted by NYU School of Medicine focuses on current issues that both pre-approval access to investigational medicines and compassionate use are currently facing.
- This site includes several videos, a meeting report, and a podcast regarding pre-approval access and compassionate use from a 2015 colloquium hosted by NYU School of Medicine and the NY Academy of Sciences and sponsored by Johnson & Johnson.
Our work with CompAC has also prompted greater awareness of the challenges surrounding compassionate use requests, an effort that has been recognized by the Fellowships at Auschwitz for the Study of Professional Ethics (FASPE). Next year, Johnson & Johnson will be honored with a 2017 FASPE Award for Ethical Leadership for our work on CompAC. The FASPE recognition is a testament to Johnson & Johnson’s unwavering commitment to ethical principles and developing programs and processes designed to advance and improve lives.